Raze Therapeutics Raises $24M in Series A Financing

Raze Therapeutics, a Cambridge, MA-based biotechnology company, closed a $24m Series A financing.

Backers included Atlas Venture, MPM Capital Management, MS Ventures, Partners Innovation Fund, Astellas Venture Management, and Novartis.

The company intends to use the funds to advance the development of a new class of therapeutics that fight cancer by targeting mitochondrial one-carbon (1C) metabolism.

Founded by Atlas Venture as a seed company and led by Peter Barrett, PhD, of Atlas Venture, who is Chairman of the board of directors, and Jason Rhodes, who is acting Chief Executive Officer, Raze Therapeutics is dedicated to the discovery and development of a new class of oncology therapeutics that target fundamental metabolic pathways essential to cancer growth and survival. By selectively targeting one-carbon (1C) metabolism using its proprietary platform, the company is developing a pipeline of 1C metabolism therapeutics across a range of solid and hematologic cancers, including genetically-defined cancers.



Join the discussion